Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer

BACKGROUND: This dose-finding study evaluated lenvatinib, an oral multitargeted receptor tyrosine kinase inhibitor, in combination with carboplatin/paclitaxel in chemotherapy-naïve non-small-cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Patients received lenvatinib twice daily (BID) with...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nishio, M, Horai, T, Horiike, A, Nokihara, H, Yamamoto, N, Takahashi, T, Murakami, H, Koizumi, F, Nishio, K, Yusa, W, Koyama, N, Tamura, T
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3738144/
https://ncbi.nlm.nih.gov/pubmed/23860537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.374
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars